TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28952176
Drug: Placebo-vehicle cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-vehicle cream
Study: 18369591
Drug: ACCM/PALS with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCM/PALS with ScvO(2) goal-directed therapy
Study: 18369591
Drug: ACCM/PALS without
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCM/PALS without ScvO(2) goal-directed therapy
Study: 12614309
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg/day
Study: 12614309
Drug: Valproate (VPA)
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate (VPA) 1250 mg/day
Study: 10940544
Drug: Self-help group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help group emphasis in treatment
Study: 7817684
Drug: KH 1060
Normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH 1060 ointment 0.2 microgram/g
Study: 7817684
Drug: KH 1060
Normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH 1060 ointment 1 microgram/g
Study: 7817684
Drug: KH 1060
Normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH 1060 ointment 0.04 microgram/g
Study: 20816031
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (4 types)
Study: 9418687
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg)
Study: 18639298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxazosin (4 to 8 mg) and finasteride (5 mg)
Study: 17054068
Drug: Recombinant vaccine
Normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine (rHAO) 45 microg
Study: 17054068
Drug: Recombinant vaccine
Normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine (rHAO) 135 microg
Study: 17054068
Drug: Commercial trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial trivalent influenza vaccine (TIV)
Study: 2239779
Drug: Continuous intragastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intragastric glucose infusion (COG)
Study: 25566971
Drug: Emotional strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional strategies employed by staff when notifying patients about treatment allocation.
Study: 23416808
Drug: No regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No regional block administered (Control)
Study: 17280633
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (1500 mg per day)
Study: 11240976
Drug: Mibefradil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (100 mg)
Study: 8923781
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (66 mg ferrous iron daily)
Study: 2573240
Drug: Melperone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone (300 mg daily)
Study: 2479227
Drug: Thiothixene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiothixene (30 mg daily)
Study: 1098177
Drug: Bismuth-protein complex
Normalized name: zinc protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-protein complex (Bicitropeptide, BCP-Compound)
Study: 25527736
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (1.4 g/day)
Study: 25527736
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (1.4 g/day) and Control meals
Study: 21690465
Drug: Regular completion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular completion of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 and Hospital Anxiety and Depression Scale with feedback to oncologists
Study: 16684940
Drug: Trauma-focused cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive-behavior treatment (CBT)
Study: 10659875
Drug: Zidovudine, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 160 mg/m2 3 times per day plus lamivudine, 4 mg/kg 2 times per day
Study: 10659875
Drug: Ritonavir, 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir, 350 mg/m2 2 times per day plus zidovudine and lamivudine
Study: 10659875
Drug: Ritonavir, 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir, 350 mg/m2 2 times per day plus stavudine, 4 mg/kg 2 times per day
Study: 9231929
Drug: Nicotinamide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide alone (80 mg kg(‐1) daily) with 52.5 Gy in 20 fractions over 4 weeks
Study: 4063284
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 or 6 g) with carbohydrate meal (80 ml Hycal)
Study: 4063284
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 or 6 g) with protein meal (150 g cooked lean minced beef)
Study: 4063284
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 or 6 g) with fat meal (200 ml double cream)
Study: 4063284
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g/l solution in water)
Study: 27163499
Drug: Ritobegron (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritobegron (20 mg) alone
Study: 27163499
Drug: Ritobegron (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritobegron (20 mg) with probenecid
Study: 22922564
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3.0 g/day
Study: 22922564
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) 0.5‐1.0 g/m(2)/month
Study: 22922564
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.0 g twice daily
Study: 22922564
Drug: Oral azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine (AZA) 2 mg/kg/day
Study: 9779768
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once)
Study: 9779768
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg twice daily for four doses)
Study: 7813328
Drug: Heparin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin followed by oral anticoagulants
Study: 7412801
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents (urokinase or streptokinase followed by heparin and then by oral anticoagulants)
Study: 27518486
Drug: Sebacoyl dinalbuphine
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sebacoyl dinalbuphine ester (SDE) injection (150 mg/2 mL)
Study: 18156032
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (fluid diet and either polyethylene glycol or sodium phosphate)
Study: 18156032
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (normal meal the day before surgery)
Study: 23390831
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation
Study: 9731794
Drug: FUT-175 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT-175 (2 mg/kg per hour) during cardiopulmonary bypass (group F)
Study: 9731794
Drug: Coincubation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coincubation with anti-interleukin-6 monoclonal antibody
Study: 7800195
Drug: Ketoprofen lysine
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen lysine salt (80 mg granular sachet)
Study: 2897812
Drug: Bevantolol (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol (100-300 mg bid)
Study: 2897812
Drug: Propranolol (80-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-240 mg bid)
Study: 2897812
Drug: Hydrochlorothiazide (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25-50 mg bid)
Study: 2897812
Drug: Both beta‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta‐adrenoceptor antagonists
Study: 31286802
Drug: Avelumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (anti-PD-L1 antibody)
Study: 31286802
Drug: Avelumab (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (as second-line treatment)
Study: 31286802
Drug: Avelumab (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (as maintenance therapy)
Study: 31286802
Drug: Avelumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (in combination with chemotherapy)
Study: 28332720
Drug: Luliconazole 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luliconazole 5% nail solution, applied once daily for 48 weeks
Study: 28332720
Drug: Vehicle, applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle, applied once daily for 48 weeks
Study: 26469083
Drug: Weight-based RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based RBV (1,000 or 1,200 mg/day)
Study: 26469083
Drug: Flat-dose RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flat-dose RBV (800 mg/day)
Study: 26469083
Drug: Weight-based RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based RBV (≥13 mg/kg/day)
Study: 26469083
Drug: Weight-based RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based RBV (<13 mg/kg/day)
Study: 17453398
Drug: Indomethacin 3
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 3 times daily for 7 days
Study: 17453398
Drug: Rofecoxib twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib twice daily for 7 days
Study: 17453398
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 7 days
Study: 12967321
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (combined pravastatin and simvastatin)
Study: 11523255
Drug: Leflunomide (LEF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) 20 mg per day
Study: 11523255
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg per week
Study: 3069466
Drug: Labetalol (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200-400 mg twice daily)
Study: 3069466
Drug: Nifedipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10-20 mg three times daily)
Study: 26324401
Drug: Glycopyrronium bromide
Normalized name: Glycopyrronium bromide
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium bromide 50 µg once daily
Study: 20524910
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide 18 µg once daily
Study: 24036725
Drug: Mg ion‐incorporated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg ion‐incorporated titanium implants
Study: 24036725
Drug: RBM surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBM surface titanium implants
Study: 17961107
Drug: HAART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART regimen with four-drug, three-class regimens
Study: 15047441
Drug: Antenatal gymnastics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal gymnastics (twice a week, 45 min sessions, 60% of maximum heart frequency)
Study: 7622826
Drug: Fluvoxamine (100‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100‐300 mg/day)
Study: 1814841
Drug: Ofloxacin 100
Normalized name: ofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 100 mg
Study: 30255188
Drug: Coloured rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloured rice polyphenol extracts (PE) from purple rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Study: 30255188
Drug: Coloured rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloured rice polyphenol extracts (PE) from red rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Study: 30255188
Drug: Coloured rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coloured rice polyphenol extracts (PE) from brown rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Study: 30255188
Drug: Brown rice
Normalized name: Brown rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown rice PE at 50 μg mL‐1
Study: 30255188
Drug: Red rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red rice PE at 50 μg mL‐1
Study: 30255188
Drug: Purple rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple rice PE at 50 μg mL‐1
Study: 27521719
Drug: 12 SQ
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 SQ HDM SLIT-tablet
Study: 24798210
Drug: West Wales
Normalized name: West Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: West Wales ADR Profile for Respiratory Medicine
Study: 20169656
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment including endoscopic haemostatic and high-dose intravenous proton-pump inhibitors
Study: 18571502
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg/day)
Study: 12367547
Drug: EMLA (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (topical anaesthetic)
Study: 26970946
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia treatment
Study: 26970946
Drug: No therapeutic
Normalized name: Gel, Multi Ingredient Topical application Gel/Jelly [AVEENO THERAPEUTIC SHAVE GEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic hypothermia treatment (control)
Study: 25252624
Drug: TNFα G‐A‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFα G‐A‐G haplotype
Study: 9141257
Drug: Paracetamol 15
Normalized name: Paracetamol 150 mg and sodium salicylate 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 15 mg/kg
Study: 16330788
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus 5 to 7 plasma exchanges of 50 mL per kg of body weight of 5% human serum albumin for 10 days
Study: 11974556
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day 17 beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Study: 11974556
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day 17 beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Study: 11974556
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day 17 beta-estradiol
Study: 11974556
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of dydrogesterone
Study: 11974556
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (irrespective of estradiol or dydrogesterone dose)
Study: 9952150
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.075 mg
Study: 9952150
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (various doses)
Study: 9952150
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.0 mg intrathecal morphine)
Study: 9952150
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.0-0.5 mg)
Study: 24965218
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions (OHI)
Study: 28646901
Drug: Ezetimibe add-on
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe add-on therapy (10 mg)
Study: 31409915
Drug: Double-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose statin therapy
Study: 23292315
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient (serum 25(OH)D ≤32 ng/mL)
Study: 23292315
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient (serum 25(OH)D >32 ng/mL)
Study: 19672935
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 microg daily)
Study: 19672935
Drug: 5-MTHF (daily)
Normalized name: (6S)-5-MTHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-MTHF (daily)
Study: 15047680
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (515 mg/day)
Study: 15047680
Drug: Antioxidant mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant mixture (515 mg vitamin C, 371 mg alpha-tocopherol, 171 mg gamma-tocopherol, 252 mg mixed tocotrienols, and 95 mg alpha-lipoic acid)
Study: 12228852
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (angiotensin receptor blocker)
Study: 2873760
Drug: Atracurium, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium, 0.5 mg/kg
Study: 8135388
Drug: Pancuronium, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium, 0.1 mg/kg
Study: 2800992
Drug: Indomethacin, 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 0.8 mg/kg i.v. preoperatively, followed by 100 mg rectally 8-hourly for 3 days
Study: 29551350
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% solution
Study: 578400
Drug: Haloprogin 1%
Normalized name: HALOPROGIN 1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloprogin 1% solution
Study: 22480102
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy only (Control)
Study: 9272427
Drug: Continuous HRT
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous HRT (25 or 50 micrograms/day of transdermal 17 beta‐estradiol plus medrogestone 5 mg/day for 12 days/month)
Study: 9272427
Drug: Ipriflavone 600
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 600 mg/day plus 17 beta‐estradiol 25 micrograms/day plus medrogestone 5 mg/day for 12 days/month
Study: 9272427
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg/day (control group)
Study: 9272427
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose HRT (not specified)
Study: 21424975
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen therapy
Study: 11810122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normobaric plus hyperbaric oxygen therapy
Study: 29131090
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control group (weekly online information on depression)
Study: 21812890
Drug: Premeal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premeal insulin glulisine
Study: 21812890
Drug: Postmeal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmeal insulin glulisine
Study: 17468795
Drug: New sling
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sling exercise therapy with home training
Study: 17468795
Drug: New sling
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sling exercise therapy without home training
Study: 10770746
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine
Study: 31744798
Drug: LOADING group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOADING group (3 monthly injections followed by as needed)
Study: 21277674
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 μg/drsp 3mg in a 24/4 regimen for 7 or 13 cycles
Study: 17434511
Drug: GnRH-a (tryptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-a (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Study: 17434511
Drug: Continuous estroprogestin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous estroprogestin (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Study: 19665279
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy (vitamins, minerals salts, lactic ferments, fish oil)
Study: 17434511
Drug: Postoperative medical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative medical and dietary therapy
Study: 15366275
Drug: Realism framework
Normalized name: Human monoclonal antibody based on an IgG1 lambda framework against human interferon gamma
DrugBank: EI-001 (DB17596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Realism framework in evidence based medicine